Report: Local unicorn Skild AI sets up an office in the San Francisco area
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
3 hours ago
- New York Post
Dave Portnoy calls out ‘morons' who think WNBA players shouldn't get more money
Dave Portnoy is fed up with those who believe WNBA players don't deserve a higher payday. In the wake of players wearing warmup shirts that said 'Pay Us What You Owe Us' at Saturday's All-Star Game, the Barstool Sports founder and owner made his stance clear with a lengthy post and subsequent video on X on Sunday. 'I don't know how anybody in the world with a brain, and maybe my brain is just bigger than most, can rationally say women don't deserve more money at this point,' Portnoy said in the video. Portnoy went on to reference how Caitlin Clark's rookie salary, $76,000, is less than what Barstool personalities Nicky Smokes and Ben Mintz make per year, calling the disparity 'insane.' As of the 2024 season, the WNBA's average salary was $147,745, according to DirecTV. Portnoy noted how some WNBA critics have referenced reports of the league losing tens of millions of dollars each year, but said the finances of the league are 'a mess, tied in with the NBA and purposely murky.' 3 Barstool Sports founder and owner Dave Portnoy thinks WNBA players deserve a pay raise. @stoolpresidente/X In October 2024, The Post reported the WNBA would be losing $40 million in the 2025 season. But, as Portnoy put it, the league is 'exploding.' 'Franchise values are exploding. Ticket sales, merch, tv rights all exploding. The players have an opt out in their CBA. Of course they took it. It's all about leverage in re-negotiations and for the 1st time in history of [the] league players have power,' Portnoy wrote. 3 Dave Portnoy attends a game between the Indiana Fever and the Connecticut Sun at TD Garden on July 15. NBAE via Getty Images The league agreed to an 11-year, $2.2 billion TV rights deal with Disney, Amazon Prime Video and NBCUniversal last summer, and TV ratings (up 23%), ticket sales (up 26%) and attendance (13%) are all surging halfway through the season, according to NPR. 'The players make virtually nothing while the entire league explodes,' Portnoy added. 'Of course they deserve more money.' Portnoy, who is one of Caitlin Clark's most vocal superfans, also refuted the notion that the league's recent success is unsustainable because it over-relies on Clark's star power. 'This league is so white hot right now, and I know everyone's going to say, 'Well, it's only Caitlin Clark, it's a one-person league,'' Portnoy said. 'Caitlin Clark was 100% the match that lit the fuse…but, Caitlin's not going anywhere. She's year two of a 15-year career.' 3 Fever star Caitlin Clark wearing a 'Pay Us What You Owe Us' shirt before the WNBA All-Star Game on July 19. Getty Images He added that other young stars like Angel Reese, Paige Bueckers and the soon-to-be pro JuJu Watkins mark a bright future for the league, too. Portnoy concluded by writing that if he could purchase a Boston-based WNBA franchise for $250 million, he 'would do it without blinking.' 'That's all you got to know about the WNBA finances,' he added.
Business Upturn
6 hours ago
- Business Upturn
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, Reckitt, and Tempus and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vestis Corporation (NYSE:VSTS), Reckitt Benckiser Group plc (OTC:RBGLY), and Tempus AI, Inc. (NASDAQ: TEM). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Vestis Corporation (NYSE:VSTS) Class Period: May 2, 2024 – May 6, 2025 Lead Plaintiff Deadline: August 8, 2025 According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. On May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.' Following this news, the price of Vestis' common stock declined dramatically. From a closing market price of $8.71 per share on May 6, 2025, Vestis' stock price fell to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day For more information on the Vestis class action go to: Reckitt Benckiser Group plc (OTC:RBGLY) Class Period: January 13, 2021 – July 28, 2024 Lead Plaintiff Deadline: August 4, 2025 Reckitt is a United Kingdom-based, global consumer goods company. To date, over 500 state and federal products liability lawsuits have been filed against Reckitt and its competitor, Abbott Laboratories ('Abbott'), claiming that they failed to adequately warn that premature infants consuming cow milk-based formulas, such as Reckitt's Enfamil and Abbott's Similac, have an increased risk of developing necrotizing enterocolitis ('NEC'), a life-threatening intestinal disease that affects premature or low birth weight infants. The Class Action alleges that, during the Class Period, Defendants made misleading statements and omissions regarding the Company's business, financial condition, and prospects. Specifically, Defendants failed to warn investors and consumers: (1) that preterm infants were at an increased risk of developing NEC by consuming Reckitt's cow's milk-based formula, Enfamil; (2) of the attendant impact on Reckitt's sales of Enfamil and Reckitt's exposure to legal claims; and (3) as a result of the above, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. For more information on the Reckitt Bensicker class action go to: Tempus AI, Inc. (NASDAQ: TEM) Class Period: August 6, 2024, and May 27, 2025 Lead Plaintiff Deadline: August 11, 2025 According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. For more information on the Elevance class action go to: About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, Walker, Esq. Marion Passmore, Esq.(212) 355-4648 [email protected]
Business Insider
7 hours ago
- Business Insider
Upcoming Stock Splits This Week (July 21 to July 25)
These are the upcoming stock splits for the week of July 21 to July 25 on TipRanks' Stock Splits Calendar. A stock split is a corporate move that increases the number of outstanding shares by issuing more to existing shareholders, all while keeping the company's total market value unchanged. This leads to a lower share price, making the stock more accessible and often more appealing to retail investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. On the flip side, some companies opt for a reverse stock split. Instead of dividing shares, they consolidate them, reducing the share count and boosting the price per share. While the market cap stays the same, this move is typically aimed at meeting minimum price requirements to maintain exchange listings, like Nasdaq's threshold, and avoid delisting. Whether the goal is to attract retail interest or preserve listing status, these corporate maneuvers can send important signals – and smart traders are always watching. Let's take a look at the upcoming stock splits for the week. Invo Fertility (IVF) – Invo Fertility, known for its innovative fertility treatments and its unique INVOcell device, is taking steps to stay in line with Nasdaq's listing requirements. On July 17, the company announced a 1-for-3 reverse stock split to help boost its share price and maintain compliance with the exchange's minimum bid rule. The split will take effect on July 21. Globavend Holdings (GVH) – Australia-based Globavend Holdings offers cross-border logistics services to e-commerce retailers, focusing on last-mile delivery and freight forwarding. On July 17, the company announced a 1-for-200 reverse stock split of its ordinary shares to increase its share price and meet Nasdaq's continued listing standards. GVH stock is expected to begin trading on a split-adjusted basis on July 21. Top Wealth Group Holding (TWG) – Hong Kong-based Top Wealth Group is engaged in environmental consulting, caviar production, and waste treatment services. On July 17, the company announced a 1-for-90 reverse stock split of its ordinary shares to regain compliance with Nasdaq's $1 minimum bid price rule and support its pending merger with Jilin Xiuzheng Agriculture & Animal Husbandry. TWG stock is expected to begin trading on a split-adjusted basis on July 21. CNS Pharmaceuticals (CNSP) – CNS Pharmaceuticals is a biotechnology company focused on developing anticancer drugs for primary and metastatic cancers of the brain and central nervous system. On July 15, the company announced a 1-for-12 reverse stock split of its common shares to comply with Nasdaq's minimum bid requirement. CNSP stock is expected to begin trading on a split-adjusted basis on July 22. Generation Bio (GBIO) – Focused on tackling rare and common genetic diseases, Generation Bio is developing next-gen non-viral gene therapies using its own closed-ended DNA platform. On July 18, the company announced a 1-for-10 reverse stock split to boost its share price and stay in compliance with Nasdaq listing rules. GBIO shares will begin trading on a split-adjusted basis starting July 22. Premium Catering Holdings (PC) – Serving up large-scale halal meals across Asia, Premium Catering Holdings is a key player in feeding construction crews and corporate events alike. On July 17, the Hong Kong-based company announced a 1-for-9 reverse stock split of its ordinary shares, a move aimed at boosting its share price and staying in line with Nasdaq's listing standards. PC stock is set to start trading on a split-adjusted basis on July 22.
